Startup Scout 23 Jun 2017 This Newly Founded French Biotech is All About Vaccines This week we visited the biotech hub Lyon, where one of our top biotechs Imaxio has recently founded Osivax to advance the development of its innovative vaccine candidates. Mission: Osivax… June 23, 2017 - 1 minutemin - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2017 €40M in Series C for a British Biotech Treating Blindness with Gene Therapy …advanced is Spark Therapeutics, in the US, which expects FDA approval for its lead candidate in retinal disease this year. A second candidate, SPK-7001, is in Phase I/II for choroidemia,… June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 25 Jul 2024 The future of inflammatory bowel disease treatment: what is on the horizon? …– Howard University AbbVie’s interest in IBD treatments isn’t waning. Last month, it bought up a preclinical candidate from Chinese biopharma FutureGen Biopharmaceutical for $150 million. The candidate FG-M701 inhibits… July 25, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 28 Jun 2024 Going nuclear: radiopharmaceuticals funding sees surge in 2024 …Biopharma’s drug candidates including its pan-cancer program targeting fibroblast activation protein-α (FAP-α), and its drug candidate for people with metastatic castration-resistant prostate cancer (mCRPC). The billion-dollar buyouts have become part… June 28, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jan 2023 Onxeo to study prostate cancer drug French biotech company Onxeo S.A. has given an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first U.S. clinical study site, Next… January 27, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2019 Celgene and Exscientia Sign the Largest Deal in AI for Drug Discovery …process of identifying promising small molecule drug candidates. “The goal is to deliver 3 preclinical candidates over 3 years,” Hopkins told me. Artificial intelligence is gaining recognition for its potential… March 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2016 Young Immuno-Oncology Biotechs attract Funding to Cure Metastasis …candidate that can block three oncological pathways. Although peptides tend to be unpopular because they usually are less specific than antibodies, their small size also facilitates manufacturing and administration. If… December 16, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 France Invests €15M in Developing a New Generation of Antibiotics …the CVI. The need for new antibiotics is pressing, but the number of candidates in the pipeline worldwide is alarmingly scarce. However, Deinove has a plan that might work where… September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Sponsored by Lumicks 14 May 2024 Cell avidity-tuning ensures safe CAR-T therapy for solid tumors …to evaluate a panel of CAR candidates for ccRCC cancer. The Harvard-based team demonstrated a key advancement with their newly developed G9 anti-CAIX CAR product, which offers potential enhancements in… May 14, 2024 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 12 Mar 2025 Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next …and EMB-09 steer ahead As approved drugs continue to be studied in the clinic to expand their approval for other cancers, there are various candidates in the clinic as well…. March 12, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 19 Sep 2024 Mitochondrial disease treatments: is a breakthrough on the horizon? …a pathway known as the PINK1/Parkin pathway that governs mitochondrial quality control. They bind to an undisclosed, novel target. The lead candidate VNA-318 is a brain-penetrant molecule that will head… September 19, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2022 Angel Pharma announces approval of IND application for clinical trial of mupadolimab …Pharma, a clinical stage biopharmaceutical company owns the rights to mupadolimab in Greater China. Mupadolimab is a humanized monoclonal antibody directed against CD73. In preclinical studies, it has demonstrated immunomodulatory… September 27, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email